

Loxo Oncology (LOXO : US\$17.65)

Loxo Oncology soars 49% in 2015, outperforming 94% of its global peers

Loxo Oncology Inc., NASDAQ's 31st largest Healthcare-Products company by market cap, soared US\$5.78 (or 48.7%) year to date in 2015 to close at US\$17.65. The stock has a 6-month USD relative strength of 94 which means in USD terms it is outperforming 94% of its 45,078 global peers. A price rise combined with a high relative strength is a bullish signal. Compared with the NASDAQ-100 Index which has risen 9.3% YTD, this is a relative price increase of 39.4%. In 2015 the market cap has jumped US\$96.1 million.

Introduction with Trends

We are currently bullish on this stock in the short-term based on technical indicators, but are more bearish in the long-term based on fundamental metrics

What makes us most bullish on the stock is the following:

- In the last three months the number of rises outnumbered falls 34:29 or 1.2:1.
- Its Moving Average Convergence Divergence indicators are rising, with its 12-day EMA higher than its 26-day EMA.
- The price to 200-day MAP ratio is 1.37, a bullish indicator.
- It is beating 96% of the market the past 6 months.

However, there are some reasons why we remain bearish on the stock for the long-term:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.6. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

Fig 1: Stock Summary

Sector	Healthcare-Products
Market Cap	US\$293.5 million
Shares Outstanding	16,629,590
ISIN	US5488621013
PermID	1-5040059115
Relative Strength (3 mo)	95

Bullish Signals

- Rises to Falls: In the last three months the number of rises outnumbered falls 34:29 or 1.2:1.
- In the NASDAQ market of 2,352 stocks traded today, the stock has a 6-month relative strength of 96 which means it is beating 96% of the market.
- A price rise combined with a high relative strength is a bullish signal.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 17.58 minus the 26-day EMA of 17.14 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The Price/MAP 200 of 1.37 for Loxo Oncology is higher than the Price/MAP 200 for the NASDAQ-100 Index of 1.3.
- The price to 200-day MAP ratio is 1.37, a bullish indicator. In the past 200 days this ratio has exceeded 1.37, eight times suggesting further upside. The stock is trading above both its MAPs and the 50-day MAP of US\$15.50 is higher than the 200-day MAP of US\$12.92, a bullish indicator. The 200-day MAP has increased to US\$12.92. An increase is another bullish indicator.

Undervaluation:

- The company is cash rich with Cash to Market Capitalisation at 15.0%.

Other Bullish Signals:

Fig 2: Bullish Indicators and Rank in Market

Description	Value	Rank In Market
Relative Strength (6M)	96	In Top 5%
Price/MAP50	1.14	In Top 7%
Price/MAP200	1.37	In Top 8%
Price Change %	1.2	In Top Quartile

Bearish Signals

Overvaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.6. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

Other Bearish Signals:

Fig 3: Bearish Indicators and Rank in Market

Description	Value	Rank In Market
Volatility %	5.5	In Bottom Quartile

Price Volume Dynamics

Fig 4: Shareholder Returns

Trailing quarter: The stock rose 34 times (54% of the time) and fell 29 times (46% of the time). The aggregate volume was 1.6 times average trading of 4.2 million shares. The value of US\$1,000 invested 3 months ago is US\$1,336 [vs 1,033 for the NASDAQ-100 Index] for a capital gain of US\$336.

PVUS\$1,000	Trailing Qtr	Trailing Yr	Trailing 3 Yrs
LOXO	US\$1,336		
Healthcare-Products sector	1,195	1,842	2,704
NASDAQ-100 Index	1,033	1,181	1,766

Fig 5: Turnover Rate & Turnover Period




Fig 6: Trailing 3 months

Turnover	US\$71.9 million
Volume	4,607,941
Volume Index (1 is avg)	1.6

Fig 7: Weekly Price Volume Dynamics (Last 12 Weeks)




Fig 8: Price/Moving Avg Price [P/MAP200]



Price Volume Dynamics (continued)

Fig 9: Trailing Price Change %

Price Change %	Quarter	Year	3 Years
LOXO	33.61		
Healthcare-Products	19.5	84.19	170.43
NASDAQ-100 index	3.3	16.7	76.59

Fig 10: YTD Comparison Stock Sector Index (%)




Fig 11: Month-on-Month Comparison (Trailing Month - ended 21st)

	21 Jul	19 Jun	21 May	21 Apr	20 Mar	20 Feb
Price 21 Jul (USD)	17.44	19.9	11.32	13.22	13.8	13.66
% Price Change	-14.1	81.1	-14.3	-1.2	1	30.1
Avg Daily Volume	47,228	45,071	38,398	37,837	37,005	35,970
VWP (USD)	15.58	13.99	12.84	12.99	12.77	11.73
Price Range (USD)	15.8 - 21.48	10.72 - 20.48	10.71 - 13.8	11.62 - 14.19	12.25 - 14.65	9.9 - 13.91
Relative Price Change %	-17.7	80.8	-16.4	-0.7	0.7	23.6
Volatility %	36	91	28.8	22.1	19.6	40.5

Fig 12: Price Volume Trend: Trailing Quarter

Fig 13: Stock v Index (Trailing Year)


Fig 14: Fibonacci Retracement



Ranking

Fig 15: Global Peer Group Analysis (all figures in USD)

Name	Relative Str. (6 mo)	MCap	PV \$1000 (1 yr)	Revenue	Net Profit	Total Assets
Nanostring Technologies	85	302.6M	1,248.5	47.6M	(50M)	102.7M
Carmat	34	294.6M	596.6		(16M)	24M
Innocoll	96	292.1M	1,638.9	4.6M	(20.7M)	48.7M
Ignyta	97	291.2M	1,689.8		(40M)	85.3M
Loxo Oncology	94	290M			(20.7M)	114.5M
CRH Medical	97	271.5M	6,192.0	12M	1.5M	79M
Sewoonmedical	63	252.3M	772.3	45M	5.4M	65.7M
Corium International	96	249.1M	1,919.6	50.3M	(13.9M)	44M
Akebia Therapeutics	73	239.3M	505.8		(123.9M)	111M

Global Peer Group Analysis (continued)

Code	Country	Last Price	P/S	P/Book	Turnover Rate (%)	% Disc to 52-w Hi
NSTG	US	US\$16.48	6.0	6.8	103.4	6.5
ALCAR	FR	EUR63.18			48.6	34.2
INNLL	US	US\$14.75	63.9	8.5	7.7	
RXDX	US	US\$14.87		5.2	226.0	23.4
LOXO	US	US\$17.44		2.6	45.1	
CRH	CA	CAD5.13	22.8		70.6	5.0
A100700	KR	KRW6,400.0	5.6	4.6	612.8	28.1
CORI	US	US\$13.84			17.2	13.4
AKBA	US	US\$11.69		2.3	274.5	56.3

Fig 16: Recent Analyst Recommendations


Date	Brokerage	Action	Past Rating	Current Rating
27-Apr-2015	Oppenheimer	Initiated Coverage	-	Outperform

Ranking (continued)

Fig 17: Rank in American Region out of 12,328 stocks

Description	Value	Rank	Quartile
MCap (US\$)	290M	3848	Second
Total Assets (US\$)	114.5M	5390	Second
Net Profit (US\$)	(20.7M)	9787	Bottom
Return on Equity %	(18.4)	6366	Third
Price to Book	2.6	4404	Second
Rel Strength 6 Mo (US\$)	96	458	Top

Fig 18: Slipping Relative Strength



Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

Financial Results (Annual)

31 December, 2014

Fig 19: Income Statement

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating expenses:			
Research and development with related party	7,568	9,384	Down 19.4
Research and development	6,947	323	Up 2,050.8
General and administrative	6,175	583	Up 959.2
Total operating expenses and loss from operations	-20,690	-10,290	Deterioration 101.1
Interest income, net	18		
Net loss	-20,672	-10,290	Deterioration 100.9
Accretion of redeemable convertible preferred stock	-34	-12	Deterioration 183.3
Net loss attributable to common stockholders	-20,706	-10,302	Deterioration 101.0
Per share information:			
Net loss per share of common stock, basic and diluted	-306.0c	-7,079.0c	Reduced 95.7
Weighted average shares outstanding, basic and diluted	6,773,673	145,528	Up 4,554.5

Fig 20: Balance Sheet

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Assets			
Current assets:			
Cash and cash equivalents	43,930	14,994	Up 193.0
Short-term investments	62,362		
Prepaid expenses with related party and other current assets	1,484	17	Up 8,629.4
Total current assets	107,776	15,011	Up 618.0
Long-term investments	6,648		
Property and equipment	12		
Security deposits	23	11	Up 109.1
Total assets	114,459	15,022	Up 661.9
Liabilities, redeemable convertible preferred stock and stockholders' -deficit equity			
Current liabilities:			
Accounts payable	239	221	Up 8.1
Accrued expenses and other current liabilities	1,548	189	Up 719.0
Total liabilities	1,787	410	Up 335.9
Commitments and contingencies			
Redeemable convertible preferred stock:			

Financial Results (Annual) (continued)

31 December, 2014

SeriesA, 0.0001 par value; 5,156,250 and 0 shares authorized at December31, 2013 and 2014, respectively; 2,812,497 and 0 shares issued and outstanding at December31, 2013 and 2014, respectively; -liquidation preference of 18,000 and 0 at December31, 2013 2014, respectively	17,799		
SeriesA-1, 0.0001 par value; 500,704 and 0 shares authorized at December31, 2013 and 2014, respectively; 500,704 and 0 shares issuedand outstanding at December31, 2013 and 2014, respectively; -liquidation preference of 12,000 and 0 at December31, 2013 and 2014, respectively	7,044		
Total redeemable convertible preferred stock	24,843		
Stockholders' -deficit equity:			
Common stock, 0.0001 par value; 9,375,000 and 125,000,000 shares 2 authorized at December31, 2013 and 2014, respectively; 452,896 and 16,644,229 shares issued and 452,896 and 16,634,063 outstanding at December31, 2013 and 2014, respectively			
Additional paid-in capital	143,660	59	Up 243,391.5
Accumulated deficit	-30,962	-10,290	Deterioration 200.9
Accumulated other comprehensive loss	-28		
Total stockholders' -deficit equity	112,672	-10,231	Recovery
Total liabilities, redeemable convertible preferred stock and stockholders' -deficit equity	114,459	15,022	Up 661.9

Fig 21: Cash Flow

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating activities:			
Net loss	-20,672	-10,290	Deterioration 100.9
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	30		
Stock-based compensation	3,049	70	Up 4,255.7
Issuance of redeemable convertible preferred stock in connection with collaboration agreement		7,044	
Changes in operating assets and liabilities:			
Prepaid expenses and other current assets	-1,244	-17	Deterioration 7,217.6
Security deposits	-12	-11	Deterioration 9.1
Accounts payable	18	221	Down 91.9
Accrued expenses and other current liabilities	1,136	189	Up 501.1
Net cash used in operating activities	-17,695	-2,794	Deterioration 533.3
Investing activities:			
Purchases of available-for-sale securities	-74,566		

Financial Results (Annual) (continued)

31 December, 2014

Proceeds from maturing available-for-sale securities	5,500		
Purchase of property	-14		
Net cash used in investing activities	-69,080		
Financing activities:			
Proceeds from issuance of redeemable convertible preferred stock, net	43,178	17,787	Up 142.8
Proceeds from the issuance of common stock	74,331	1	Up 7,433,000.0
Payment of deferred financing fees	-1,798		
Net cash provided by financing activities	115,711	17,788	Up 550.5
Net increase in cash and cash equivalents	28,936	14,994	Up 93.0
Cash and cash equivalentsbeginning of period	14,994		
Cash and cash equivalentsend of period	43,930	14,994	Up 193.0

Fig 22: Performance Ratios

	2014-12-31	2013-12-31	Change %
Return on Equity (%)	-18.38		
Return on Assets (%)	-18.09	-68.58	Reduced 73.6
Total Liabilities to Operating Cash Flow	-0.1	-0.15	Reduced 31.2
Total Liabilities/Total Assets	0.02	0.03	Down 42.8

Fig 23: Per Share figures

	2014-12-31	2013-12-31	Change %
Cash	US\$6.49	US\$103.03	Down 93.7
Shareholders' Funds	US\$16.63	-7,030.26c	Recovery
Total Liabilities	26.38c	US\$2.82	Down 90.6
Total Assets	US\$16.90	US\$103.22	Down 83.6
Net Tangible Assets	US\$16.63	-7,030.26c	Recovery
EPS Final	-306.0c	-7,079.0c	Reduced 95.7

Company Overview and Regulatory Announcements

Activities

Loxo Oncology Inc researches and develops cancer drugs. The company focuses on building small molecule cancer drugs for genetically defined patient subsets.

Further details can be found at
<http://www.loxooncology.com>.

Business Sector	Healthcare Services
Industry Group	Healthcare Equipment & Supplies
Economic Sector	Healthcare

Issued Capital


Based on 16,629,590 issued equity shares the market capitalisation is US\$293.5 million.

The top fifteen shareholders hold 46.0% of the issued capital leaving a float of 54.0%.

Fig 24: List of Top 10 Institutional Holdings

Name of Shareholder	No. of Shares	% Held	Value USD
Orbimed Advisors LLC	2,175,857	13.08	38.4 M
Deerfield Management Co	1,591,546	9.57	28.1 M
BVF Inc,IL	1,125,665	6.77	19.9 M
RS Investment Management Co LLC	834,041	5.02	14.7 M
Visium Asset Management Lp	425,000	2.56	7.5 M
Driehaus Capital Management LLC	382,021	2.3	6.7 M
Millennium Management LLC	309,516	1.86	5.5 M
Ghost Tree Capital LLC	175,000	1.05	3.1 M
Axa	143,694	0.86	2.5 M
Eventide Asset Management LLC	114,600	0.69	2 M
Total	7,276,940	43.76	

Fig 25: Top 15 Institutional Holdings as % of total



Financials

Annual Report for the year ended December 31, 2014

year-on-year comparisons with previous corresponding period

Unfavourable Changes

- Operating cash flow is negative.

Major Common Size Ratios

- Total current assets to total assets down from 99.9% to 94.2%
- Cash to total assets down from 99.8% to 38.4%.

8-K people news

June 10: Loxo Oncology Elects 2 Directors

Loxo Oncology (LOXO) held its Annual General Meeting on June 10, 2015. According to an SEC filing under Section 8-K Item 5.07 the following directors were elected:

James Barrett
Joshua H. Bilenker

October 28: Dov A. Goldstein - Loxo Oncology director resigns 29 October 2014

Dov A. Goldstein has resigned from Loxo Oncology as Director. The resignation takes effect from Oct 23, 2014.

October 28: Loxo Oncology appoints Lori Kunkel as director 29 October 2014

Loxo Oncology has appointed Lori Kunkel as Director. The appointment takes effect from Oct 23, 2014.

Regulatory Announcements (continued)

8-K other news

May 14: Loxo Oncology: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1581720_000110465915037864_0001104659-15-037864.txt

Source: 8-K United States Securities and Exchange Commission

March 27: Loxo Oncology: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1581720_000110465915023228_0001104659-15-023228.txt

Source: 8-K United States Securities and Exchange Commission

November 14: Loxo Oncology: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1581720_000110465914080641_0001104659-14-080641.txt

Source: 8-K United States Securities and Exchange Commission

September 12: Loxo Oncology: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1581720_000110465914065966_0001104659-14-065966.txt

Source: 8-K United States Securities and Exchange Commission

Changes in Board and Management

January 12: Loxo Oncology appoints Independent Director

Loxo Oncology has appointed Alan Fuhrman as Independent Director. The effective date is January 12, 2015.

October 28 2014: Loxo Oncology Appoints Chief Medical Officer, New Director

STAMFORD, Conn., Oct. 28, 2014 -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced the promotion of Jennifer Low, M.D., Ph.D. to Chief Medical Officer (CMO) and the appointment of Lori Kunkel, M.D.

[For more details click here.](#)

Annual Meetings

June 02: Loxo Oncology announces AGM

Loxo Oncology has announced its Annual General Meeting will take place on June 10, 2015.

Performance

March 27: Loxo Oncology Announces Fourth Quarter and Year-End 2014 Financial Results

[News Story] STAMFORD, Conn., March 27, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today reported fourth quarter and year-end 2014 financial results. Loxo Oncology will not be conducting a conference call in conjunction with this earnings release.

[For more details click here.](#)

November 07 2014: Loxo Oncology to Announce Third Quarter 2014 Financial Results

[News Story] STAMFORD, Conn., Nov. 7, 2014 -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, will announce financial results for the third quarter ended September 30, 2014 on November 14, 2014 before the NASDAQ market open.

[For more details click here.](#)

September 12 2014: Loxo Oncology Announces Second Quarter 2014 Financial Results

[Company Release] STAMFORD, Conn., Sept. 12, 2014 Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today reported financial results for the quarter ended June 30, 2014 and recent business highlights.

Press Releases

June 17: Loxo Oncology To Present At The Jmp Securities Life Sciences Conference

[News Story] STAMFORD, Conn., June 17, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 24, 2015 at 11:30AM Eastern Time. A live webcast of the presentation will be available at <http://ir.loxooncology.com/>.

About Loxo Oncology

<http://www.nasdaq.com/press-release/loxo-oncology-to-present-at-the-jmp-securities-life-sciences-conference-20150617-00172>>Read more...

Source: Nasdaq Stock Exchange

[For more details click here.](#)

Regulatory Announcements (continued)

June 10: Loxo Oncology: Submission of Matters to a Vote of Security Holders

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1581720_000110465915044581_0001104659-15-044581.txt

Source: 8-K United States Securities and Exchange Commission

June 09: Loxo Oncology, Inc. (nasdaq:loxo) To Ring The Nasdaq Stock Market Closing Bell

[News Story] ADVISORY, June 09, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Dr. Joshua H. Bilenker M.D., Chief Executive Officer will ring the Closing Bell.

[Read more...](http://www.nasdaq.com/press-release/loxo-oncology-inc-nasdaqloxo-to-ring-the-nasdaq-stock-market-closing-bell-20150609-00655)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

May 14: Loxo Oncology: Loxo Oncology Announces First Quarter 2015 Financial Results

[News Story] STAMFORD, Conn., May 14, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today reported first quarter 2015 financial results and recent business highlights.

"In the first quarter of 2015 we demonstrated strong progress in our pipeline, including the presentation of initial clinical data for LOXO-101 at AACR and the unveiling of three additional preclinical programs. Our focus on targeted cancer therapies with best-in-class potential reflects our belief that selective, rationally designed drugs can demonstrate clinical benefit and differentiation when tested in patients with the relevant oncogene addicted tumors," said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. "We are pleased that initial data from our Phase 1a trial of LOXO-101 show that the drug is achieving biologically relevant exposures, while revealing no clear drug-related safety signals. We look forward to moving into exclusively TRK-altered patients in the second half of the year and continuing to advance our pipeline."

Recent Business Highlights

[Read more...](http://www.nasdaq.com/press-release/loxo-oncology-announces-first-quarter-2015-financial-results-20150514-00158)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

May 08: Loxo Oncology to Announce First Quarter 2015 Financial Results

[News Story] STAMFORD, Conn., May 8, 2015 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, will announce financial results for the quarter ended March 31, 2015 on May 14, 2015 before the NASDAQ market open.

[For more details click here.](#)

April 21: Loxo Oncology LOXO-101 Demonstrates Encouraging Initial Results From Ongoing Phase 1a Dose Escalation Study

[News Story] STAMFORD, Conn., April 21, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced the presentation of initial Phase 1a safety and pharmacokinetic data for LOXO-101, the only selective inhibitor of the TRK family of tyrosine kinase receptors in clinical development, in a poster session at the American Association for Cancer Research (AACR) 2015 Annual Meeting in Philadelphia, PA.

[For more details click here.](#)

March 03: Loxo Oncology Announces 2015 Program Guidance and Reveals Selected Pipeline Programs

[News Story] STAMFORD, Conn., March 2, 2015 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today provided updated 2015 program guidance and unveiled molecular targets for three of its active preclinical programs.

[For more details click here.](#)

February 23: Events Calendar: Loxo Oncology Announces Date of 2015 Program Guidance Webcast and Conference Call

[News Story] STAMFORD, Conn., Feb. 23, 2015 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that the Company's management team will host a webcast and conference call on Monday, March 2, 2015 at 8:00 am ET to discuss the Company's program guidance for 2015.

[For more details click here.](#)

February 04: Loxo Oncology to Present at Upcoming Investor Conferences

[News Story] STAMFORD, Conn., Feb. 4, 2015 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that Joshua H. Bilenker, M.D., Chief Executive Officer will present a corporate overview at two upcoming conferences.

[For more details click here.](#)

Regulatory Announcements (continued)

November 12 2014: Loxo Oncology to Present at Upcoming Investor Conferences

[News Story] STAMFORD, Conn., Nov. 12, 2014 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced that Joshua H. Bilenker, M.D., Chief Executive Officer, will present a corporate overview at several upcoming conferences.

Details of the conferences are as follows:

Stifel 2014 Healthcare Conference, November 19 at 11:30 AM, New York Palace Hotel, New York, NY Piper Jaffray 26th Annual Healthcare Conference, December 2 at 9:00 AM, New York Palace Hotel, New York, NY Oppenheimer 25th Annual Healthcare Conference, December 11 at 1:35 PM, Crowne Plaza Hotel, New York, NY

Webcast links for all presentations can be found at <http://ir.loxooncology.com/>.

Source: Nasdaq Stock Exchange

[For more details click here.](#)

October 30 2014: Loxo Oncology to Present Pre-Clinical Data on LOXO-101 at Upcoming EORTC-NCI-AACR Symposium

[News Story]

<link><http://www.nasdaq.com/press-release/loxo-oncology-to-present-preclinical-data-on-loxo101-at-upcoming-eortcnciacr-symposium-20141030-00362></link>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

September 05 2014: Loxo Oncology Announces Closing of Initial Public Offering and Partial Exercise of Over-Allotment Option

[Company Release] STAMFORD, Conn. Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced the closing of the initial public offering of 5,903,538 shares of its common stock, including 642,000 shares of common stock that were issued upon the exercise of the underwriters' over-allotment option to purchase additional shares, at a price to the public of \$13.00 per share.

September 05 2014: Loxo Oncology to Announce Second Quarter 2014 Financial Results

[Company Release] STAMFORD, Conn., Sept. 5, 2014 Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, will announce financial results for the quarter ended June 30, 2014 on September 12, 2014 before the NASDAQ market open.

August 01 2014: Loxo Oncology Announces Pricing of Initial Public Offering

[Company Release] STAMFORD, Conn., Aug. 1, 2014 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced the pricing of its initial public offering of 5,261,538 shares of its common stock at a price to the public of \$13.00 per share.

Board and Management & creation of shareholder value

Joshua H. Bilenker CEO & President

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, has served as President and Chief Executive Officer since June 2013 and as a member of our board of directors since June 2013. Since November 2013, Dr. Bilenker has served as an Operating Partner at Aisling Capital LLC, or Aisling Capital, a private equity firm, where he was a Partner from January 2012 to October 2013 and previously served as a Principal from October 2008 to December 2011 and an Associate from April 2006 to September 2008. Dr. Bilenker is on the board of directors of T2 Biosystems and Viewray Inc. He also serves on the nonprofit boards of BioEnterprise and The NCCN Foundation. From 2004 to 2006, Dr. Bilenker served as a Medical Officer at the FDA in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University. We believe that Dr. Bilenker should serve on our board of directors due to his thorough knowledge of our company and his experience in finance and medicine.

Remuneration:

Year: 2014

Salary (\$): 350,000

Option Awards (\$): 5,373,108

Total (\$): 5,723,108

Keith T. Flaherty Director

Dr. Keith T. Flaherty has served as a member of our board of directors since September 2013. He is Director of the Henri and Belinda Termeer Center for Targeted Therapy and Clinical Research, Massachusetts General Hospital Cancer Center, and is an Associate Professor of Medicine at Harvard Medical School. He has worked as a physician at Massachusetts General Hospital since 2009. Dr. Flaherty serves on the board of directors of Clovis Oncology, Inc., a biopharmaceutical company. Dr. Flaherty trained in internal medicine at Brigham and Women's Hospital, and in medical oncology at the University of Pennsylvania, earning board certifications in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree in Neurobiology from Yale University. We believe that Dr. Flaherty should serve on our board of directors due to his scientific background and experience as a clinician in the field of oncology.

James Barrett Director

Dr. James Barrett has served on the board of directors since April 2014. Since 2001, he has served as a General Partner of New Enterprise Associates, or NEA, a venture capital firm, where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA, from 1997 to 2001, Dr. Barrett founded and served as Chairman and Chief Executive Officer at Sensors for Medicine and Science, a medical device company. In addition to serving on our board of directors, Dr. Barrett currently serves on the boards of several biopharmaceutical and biotechnology companies, including Clovis Oncology, Inc., Roka Bioscience, Inc., GlycoMimetics, Inc., Zosano Pharma Corporation and Supernus Pharmaceuticals, Inc. He also serves on the board of directors of several private companies. He previously served on the boards of Inhibitex, Inc. from 2002 to 2012 and Targacept, Inc. from 2002 to 2013. Dr. Barrett received his Ph.D. in Biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara and his B.S. in Chemistry from Boston College. We believe that Dr. Barrett should serve on our board of directors due to his experience overseeing investments in biotechnology, service on the board of directors of several public biopharmaceutical companies and prior senior management experience in the biopharmaceutical sector.

Avi Z. Naider Director

Avi Z. Naider has served as a member of our board of directors since September 2013. Mr. Naider is Chairman and CEO of ACES Risk Management Corp., a software company, a position he has held since January 2008. Mr. Naider is also a private investor and consultant to various companies. Prior to joining ACES, Mr. Naider founded an internet advertising software company, worked in private equity and was an associate at the Boston Consulting Group. Mr. Naider received his A.B. in the Woodrow Wilson School of Public and International Affairs from Princeton University. We believe that Mr. Naider should serve on our board of directors due to his experience founding and managing companies.

Board and Management & creation of shareholder value (continued)

David Bonita Director

Dr. David Bonita has served as a member of our board of directors since September 2013. Dr. Bonita has been a Private Equity Partner at OrbiMed Advisors LLC, or OrbiMed LLC, an investment company, since June 2012. Previously, Dr. Bonita served in various roles at OrbiMed LLC, including as a Private Equity Principal from December 2007 to June 2012 and as a Senior Associate from June 2004 to December 2007. In addition to serving on our board of directors, Dr. Bonita has served on the boards of directors of Ambit Biosciences Corporation, a biopharmaceutical company, since 2012 and of several private companies. Prior to joining OrbiMed LLC, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS AG. Dr. Bonita received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University. We believe that Dr. Bonita should serve on our board of directors because of his private equity expertise and knowledge of the healthcare industry.

Steve Elms Director

Steven A. Elms has served as a member of our board of directors since July 2013. He currently serves as a Managing Partner of Aisling Capital LLC, a private equity firm. He joined Aisling Capital LLC in 2000 from the life sciences investment banking group of Chase H&Q (formerly Hambrecht and Quist Group Inc.) where he was a principal. Mr. Elms serves on the board of directors of Pernix Therapeutics Holdings, Inc. and ADMA Biologics, Inc. Previously, Mr. Elms served on the board of directors of Ambit Biosciences Corp. from 2001 to 2014, MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received his B.A. in Human Biology from Stanford University and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University. We believe that Mr. Elms should serve on our board of directors due to his extensive financial services background and experience in the pharmaceutical and healthcare industries.

Lori Kunkel Director

Dr. Lori Kunkel has served on the board of directors since October 2014. She previously served as Acting Chief Medical Officer for Loxo Oncology. Prior to Loxo, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, a biopharmaceutical company, from November 2011 until August 2013 where she was responsible for building and leading an integrated clinical development and medical affairs organization highlighted by the approval of IMBRUVICA. From February 2009 until joining Pharmacyclics she served as a clinical advisor to Syndax, a biopharmaceutical company. Previously she served as Chief Medical Officer at Proteolix, a biotechnology company acquired by Onyx, where she oversaw the clinical development of KYPROLIS. She has held senior roles at ACT Therapeutics, Xencor, and Genitope. Dr. Kunkel trained in internal medicine at Baylor College of Medicine, and in hematology-oncology at USC and UCLA, earning board certification in these specialties. Dr. Kunkel received her M.D. from University of Southern California and her B.A. degree from University of California San Diego. We believe that Dr. Kunkel should serve on our board of directors due to her clinical development expertise and experience in the biopharmaceutical industry.

Creation of shareholder value in Loxo Oncology:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of October 23, 2014 at close price of US\$11.21 is US\$1,575, for a capital gain of US\$575.

Alan Fuhrman Independent Director

Alan Fuhrman has served as a member of our board of directors since January 2015. He previously served as the chief financial officer of Ambit Biosciences from October 2010 until its recent sale to Daiichi Sankyo for up to \$410 million. Prior to this role, he served as chief financial officer of Naviscan, Inc., a privately-held medical imaging company from November 2008 until September 2010, and as chief financial officer of Sonus Pharmaceuticals from September 2004 until August 2008. Earlier in Mr. Fuhrman's career he practiced as a CPA with Coopers and Lybrand. Mr. Fuhrman received B.S. degrees in both business administration and agricultural economics from Montana State University. We believe that Mr. Fuhrman should serve on our board of directors based on his financial expertise and his experience with public company accounting.

Creation of shareholder value in Loxo Oncology:

Since appointment as Independent Director: The present value of USD1,000 invested on the appointment date of January 12, 2015 at close price of US\$11.35 is US\$1,555, for a capital gain of US\$555.

Glossary

Capital Gain/Loss from n Years Ago to n-1 Years Ago:

Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

Moving Average Price (n periods) (Fig 2, 8):

Sum of Prices for each Period/Number of Periods

Price Close/Moving Avg Price (Fig 2, 8):

Latest Price/Moving Average Price

Price/Sales (Fig 16):

Share Price/Sales Per Share (times)

Relative Strength (n-th Period) (Fig 1, 2, 18, 17, 15):

Price close today/Price close 'n' periods ago, then ranked by percentile within the entire market.

Return on Equity (Shareholders' Funds) (Fig 17, 23):

Net Profit/Net Assets (%)

Turnover Period (Fig 5):

Time Period required for trading all Outstanding Shares

Volatility (Fig 3, 11):

Highest Price minus Lowest Price/Lowest Price (%)

Volume Weighted Price (VWP) (Fig 11):

The Volume Weighted Price (VWP) is the summation of turnover divided by total volume in the same period.

Cash/MCap:

Cash plus Liquids/Market Capitalisation (times)

PVUS\$1000 (Fig 4):

Present value of US\$1000 invested 1 year/'n' years ago

Price/NTA (Fig 17, 16):

Closing Share Price/Net Tangible Assets Per Share (times)

Relative Price Change (Fig 11):

Today's Relative price change with respect to Benchmark Index

Return on Assets (Fig 23):

Net Profit/Total Assets (%)

Turnover (Fig 6):

Last Price * Volume

Turnover Rate (Fig 16, 5):

US Dollar value of annual trading volume as a percentage of market capitalisation

Volume Index (Fig 6):

Number of shares traded in the period/Average number of shares traded for the period

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

For further details on definitions and quotations from investing legends, [Click here](#)

For any enquiries, please email: feedback@buysellsignals.com

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756), who provide round the clock data on every stock and sector. BuySellSignals is not a broker, and does not have an executing, corporate advisory or investment banking function. BuySellSignals, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.